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HEALTH CARE UTILIZATION, COST AND MEDICATION USE
AMONG PEDIATRIC ASTHMA PATIENTS
Modi A, Iyer R, Lawrence L
University of Louisiana at Monroe, Monroe, LA, USA
Asthma is the most prevalent chronic condition in children and
is the number one cause of childhood hospitalizations. Revised
guidelines published by the National Institutes of Health in 1997
characterize asthma as a chronic, inﬂammatory disease and
propose speciﬁc recommendations for therapy with inhaled anti-
inﬂammatory medications and stress the importance of ambula-
tory care to achieve adequate control. Given the high prevalence
and current emphasis on monitoring asthma care by interven-
tion, it is important to evaluate its economic impact on the health
care system. OBJECTIVE: To estimate costs, health care utiliza-
tion and characterize medication use of pediatric asthma patients
in the post-guidelines era (1999–2001). METHODS: Data for
this study were derived from the 1999–2001 household compo-
nent of the Medical Expenditure Panel Survey. Pediatric asthma
patients (age °Ü 17yrs) were identiﬁed based on ICD-9-CM code
of 493. Total costs were computed in terms of direct medical
expenditures and indirect costs (based on school days or work
days missed by caregiver). All costs were computed in terms of
2003 US dollars. RESULTS: Average annual cost per-child for
1999, 2000, and 2001 was $512.37, $572.27, and $662.31
respectively. In 1999, hospitalization was the major cost driver
followed by ofﬁce-based-visits and prescription medications.
However, in 2000 and 2001, ofﬁce-based-visits were the major
cost drivers followed by prescription medications. Long-term
control medications were prescribed more frequently than quick
relief medications. Inhaled anti-inﬂammatory medications were
prescribed less when compared to other medications in the same
category. CONCLUSIONS: The study data show an increase in
the use and cost of ofﬁce-based-visits, medications and a decrease
in hospitalization costs. These ﬁndings suggest that there have
been improvements in care, consistent with the guidelines. Infor-
mation from this study can help track changes in treatment of
asthma and how the order of cost drivers has changed during
this time.
PAS2
IMPACT OF ANTI-INFLAMMATORY MEDICATION ON ASTHMA
COSTS IN A PEDIATRIC POPULATION
Sapra SJ1, Martin BC2, Dorfman JH3
1University of California, San Francisco, CA, USA; 2University of
Arkansas for Medical Sciences, Little Rock, AR, USA; 3University of
Georgia, Athens, GA, USA
OBJECTIVE: Anti-inﬂammatory medication may interrupt the
progression to and severity of asthma for pediatrics who suffer
from allergic rhinitis (AR) and/or atopic dermatitis (AD). The
objective of this study was to evaluate the impact of: ﬁrst 
generation anti-histamines (FGAH), second generation anti-
histamines (SGAH), and intra-nasal steroids (INS) on annual
asthma treatment costs in a cohort of AD/AR patients who
develop asthma. METHODS: Data from GA Medicaid (1995 to
2001) and MarketScan (commercial population—1998 to 2001)
were utilized. Newborn children free of any malignancies and
diagnosed with AD/AR who later developed asthma and were
eligible for at least 12 months after the ﬁrst asthma diagnosis
were included. All FGAH, SGAH and INS prescriptions from
birth until an asthma diagnosis were recorded and total direct
health care costs for subjects in the AD/AR cohort after the ﬁrst
asthma diagnosis were examined. Multivariate ordinary least
squares regression using Huber-white heteroscedasticity consis-
tent variance–covariance matrix after adjusting for sample selec-
tion was used to compare direct medical costs between groups
exposed to FGAH, SGAH or INS and groups with no exposure.
RESULTS: In total, 4277 in GA Medicaid and 353 asthma
patients in the commercial were included, of which 2906 (68%)
and 228 (64%) patients had at least one prescription for FGAH,
SGAH, and INS. Any exposure to these anti-inﬂammatory agents
were associated with a non-signiﬁcant lower mean total cost of
$66 PMPY (p-value = 0.50) and $497 PMPY (p-value = 0.45) in
the GA Medicaid and commercial populations. Total medical
costs (excluding prescriptions) and physician costs were $733 (p-
value = 0.04) and $303 PMPY (p-value = 0.05) lower for the
exposure groups in the commercial population. CONCLUSION:
Exposure to anti-inﬂammatory agents reduced medical costs
excluding prescription drugs in a commercial population;
however, medical costs were not signiﬁcantly lower in the 
Medicaid population.
PAS3
A COMPARISON OF ASTHMA MEDICATION USE IN PUBLICLY
VERSUS PRIVATELY INSURED CHILDREN WITH ASTHMA
Ungar WJ1, Kozyrskyj A2, Paterson M3, Mamdani M3, Gunraj N3,
Ahmad F4
1The Hospital for Sick Children,Toronto, ON, Canada; 2Manitoba
Centre for Health Policy, Winnipeg, MB, Canada; 3Institute for Clinical
Evaluative Sciences,Toronto, ON, Canada; 4Brogan Inc, Ottawa, ON,
Canada
OBJECTIVES: Asthma is the most common chronic disease in
childhood. To ensure optimal control, children must have access
to necessary medications, including inhaled corticosteroids for
maintenance and bronchodilators as needed. The objective was
to compare asthma medication use in publicly insured social
assistance children to privately insured children with asthma.
METHODS: Identical case deﬁnitions were used to created
public (n = 12,767) and private (n = 17,046) cohorts of asth-
matic Ontario children aged 2–14 years using 2002 aggregate
private sector claims and 1998–2001 Ontario Drug Beneﬁts
database claims. Use of bronchodilators (BD), inhaled corticos-
teroids (ICS), leukotriene antagonists (LA) and oral corticos-
teroids (OS) were compared between cohorts. RESULTS: In
contravention of guidelines, 12% of social assistance children
received BD monotherapy compared to 1% of privately insured
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